The role of claudin-5 in blood-brain barrier (BBB) and brain metastases (Review)

Molecular Medicine Reports

Volumn 9, Issue 3, 2014, Pages 779-785

  Jia, Wang ^a   Lu, Runchun ^a   Martin, Tracey A ^b   Jiang, Wen G ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Blood brain barrier; Brain metastases; Claudin 5; Claudins; Permeability; Tight junctions

Indexed keywords

BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CLAUDIN-5; ENDOTHELIAL CELLS; HUMANS; JUNCTIONAL ADHESION MOLECULES; NEOPLASM METASTASIS; TIGHT JUNCTIONS;

EID: 84893844241     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1875     Document Type: Article

References (72)

1. Wilhelm I, Molnár J, Fazakas C, Haskó J and Krizbai IA: Role of the blood-brain barrier in the formation of brain metastases. Int J Mol Sci 14: 1383-1411, 2013.
2. Walker AE, Robins M and Weinfeld FD: Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology 35: 219-226, 1985.
3. Gavrilovic IT and Posner JB: Brain metastases: epidemiology and pathophysiology. J Neurooncol 75: 5-14, 2005.
4. Schouten LJ, Rutten J, Huveneers HA and Twijnstra A: Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94: 2698-2705, 2002.
5. Preusser M, Capper D, Ilhan-Mutlu A, et al: Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol 123: 205-222, 2012.
6. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P and Sawaya RE: Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22: 2865-2872, 2004.
7. Platta CS, Khuntia D, Mehta MP and Suh JH: Current treatment strategies for brain metastasis and complications from therapeutic techniques: a review of current literature. Am J Clin Oncol 33: 398-407, 2010.
8. Lim LC, Rosenthal MA, Maartens N and Ryan G: Management of brain metastases. Intern Med J 34: 270-278, 2004.
9. Lu-Emerson C and Eichler AF: Brain metastases. Continuum (Minneap Minn) 18: 295-311, 2012.
10. Delattre JY, Krol G, Thaler HT and Posner JB: Distribution of brain metastases. Arch Neurol 45: 741-744, 1988.
11. Gaspar LE, Mehta MP, Patchell RA, et al: The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96: 17-32, 2010.
12. Linskey ME, Andrews DW, Asher AL, et al: The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96: 45-68, 2010.
13. Mehta MP, Paleologos NA, Mikkelsen T, et al: The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96: 71-83, 2010.
14. Kalkanis SN, Kondziolka D, Gaspar LE, et al: The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96: 33-43, 2010.
15. Olson JJ, Paleologos NA, Gaspar LE, et al: The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. J Neurooncol 96: 115-142, 2010.
16. Fokas E, Steinbach JP and Rödel C: Biology of brain metastases and novel targeted therapies: time to translate the research. Biochim Biophys Acta 1835: 61-75, 2013.
17. Correale J and Villa A: Cellular elements of the blood-brain barrier. Neurochem Res 34: 2067-2077, 2009.
18. Bearer EL and Orci L: Endothelial fenestral diaphragms: a quick-freeze, deep-etch study. J Cell Biol 100: 418-428, 1985.
19. Brightman MW and Reese TS: Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol 40: 648-677, 1969.
20. Lane NJ, Reese TS and Kachar B: Structural domains of the tight junctional intramembrane fibrils. Tissue Cell 24: 291-300, 1992.
21. Villegas JC and Broadwell RD: Transcytosis of protein through the mammalian cerebral epithelium and endothelium. II. Adsorptive transcytosis of WGA-HRP and the blood-brain and brain-blood barriers. J Neurocytol 22: 67-80, 1993.
22. Wilhelm I, Molnár J, Fazakas C, Haskó J and Krizbai IA: Role of the blood-brain barrier in the formation of brain metastases. Int J Mol Sci 14: 1383-1411, 2013.
23. Walker AE, Robins M and Weinfeld FD: Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology 35: 219-226, 1985.
24. Gavrilovic IT and Posner JB: Brain metastases: epidemiology and pathophysiology. J Neurooncol 75: 5-14, 2005.
25. Schouten LJ, Rutten J, Huveneers HA and Twijnstra A: Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94: 2698-2705, 2002.
26. Preusser M, Capper D, Ilhan-Mutlu A, et al: Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol 123: 205-222, 2012.
27. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P and Sawaya RE: Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22: 2865-2872, 2004.
28. Platta CS, Khuntia D, Mehta MP and Suh JH: Current treatment strategies for brain metastasis and complications from therapeutic techniques: a review of current literature. Am J Clin Oncol 33: 398-407, 2010.
29. Lim LC, Rosenthal MA, Maartens N and Ryan G: Management of brain metastases. Intern Med J 34: 270-278, 2004.
30. Lu-Emerson C and Eichler AF: Brain metastases. Continuum (Minneap Minn) 18: 295-311, 2012.
31. Delattre JY, Krol G, Thaler HT and Posner JB: Distribution of brain metastases. Arch Neurol 45: 741-744, 1988.
32. Gaspar LE, Mehta MP, Patchell RA, et al: The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96: 17-32, 2010.
33. Linskey ME, Andrews DW, Asher AL, et al: The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96: 45-68, 2010.
34. Mehta MP, Paleologos NA, Mikkelsen T, et al: The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96: 71-83, 2010.
35. Kalkanis SN, Kondziolka D, Gaspar LE, et al: The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96: 33-43, 2010.
36. Olson JJ, Paleologos NA, Gaspar LE, et al: The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. J Neurooncol 96: 115-142, 2010.
37. Fokas E, Steinbach JP and Rödel C: Biology of brain metastases and novel targeted therapies: time to translate the research. Biochim Biophys Acta 1835: 61-75, 2013.
38. Correale J and Villa A: Cellular elements of the blood-brain barrier. Neurochem Res 34: 2067-2077, 2009.
39. Bearer EL and Orci L: Endothelial fenestral diaphragms: a quick-freeze, deep-etch study. J Cell Biol 100: 418-428, 1985.
40. Brightman MW and Reese TS: Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol 40: 648-677, 1969.
41. Lane NJ, Reese TS and Kachar B: Structural domains of the tight junctional intramembrane fibrils. Tissue Cell 24: 291-300, 1992.
42. Villegas JC and Broadwell RD: Transcytosis of protein through the mammalian cerebral epithelium and endothelium. II. Adsorptive transcytosis of WGA-HRP and the blood-brain and brain-blood barriers. J Neurocytol 22: 67-80, 1993.
43. Morita K, Sasaki H, Furuse K, Furuse M, Tsukita S and Miyachi Y: Expression of claudin-5 in dermal vascular endothelia. Exp Dermatol 12: 289-295, 2003.
44. Rahner C, Mitic LL and Anderson JM: Heterogeneity in expression and subcellular localization of claudins 2, 3, 4, and 5 in the rat liver, pancreas, and gut. Gastroenterology 120: 411-422, 2001.
45. Biazik JM, Thompson MB and Murphy CR: Claudin-5 is restricted to the tight junction region of uterine epithelial cells in the uterus of pregnant/gravid squamate reptiles. Anat Rec (Hoboken) 291: 547-556, 2008.
46. Amasheh S, Schmidt T, Mahn M, et al: Contribution of claudin-5 to barrier properties in tight junctions of epithelial cells. Cell Tissue Res 321: 89-96, 2005.
47. Ohtsuki S, Ikeda C, Uchida Y, et al: Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC/D3 as a human blood-brain barrier model. Mol Pharm 10: 289-296, 2013.
48. Wen H, Watry DD, Marcondes MC and Fox HS: Selective decrease in paracellular conductance of tight junctions: role of the first extracellular domain of claudin-5. Mol Cell Biol 24: 8408-8417, 2004.
49. Piontek J, Fritzsche S, Cording J, et al: Elucidating the principles of the molecular organization of heteropolymeric tight junction strands. Cell Mol Life Sci 68: 3903-3918, 2011.
50. Kluger MS, Clark PR, Tellides G, Gerke V and Pober JS: Claudin-5 controls intercellular barriers of human dermal microvascular but not human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol 33: 489-500, 2013.
51. Yang Y and Rosenberg GA: MMP-mediated disruption of claudin-5 in the blood-brain barrier of rat brain after cerebral ischemia. Methods Mol Biol 762: 333-345, 2011.
52. Liu C, Wu J and Zou MH: Activation of AMP-activated protein kinase alleviates high-glucose-induced dysfunction of brain microvascular endothelial cell tight-junction dynamics. Free Radic Biol Med 53: 1213-1221, 2012.
53. Balbuena P, Li W and Ehrich M: Assessments of tight junction proteins occludin, claudin 5 and scaffold proteins ZO1 and ZO2 in endothelial cells of the rat blood-brain barrier: cellular responses to neurotoxicants malathion and lead acetate. Neurotoxicology 32: 58-67, 2011.
54. Helms HC, Waagepetersen HS, Nielsen CU and Brodin B: Paracellular tightness and claudin-5 expression is increased in the BCEC/astrocyte blood-brain barrier model by increasing media buffer capacity during growth. AAPS J 12: 759-770, 2010.
55. Ishizaki T, Chiba H, Kojima T, et al: Cyclic AMP induces phosphorylation of claudin-5 immunoprecipitates and expression of claudin-5 gene in blood-brain-barrier endothelial cells via protein kinase A-dependent and-independent pathways. Exp Cell Res 290: 275-288, 2003.
56. Soma T, Chiba H, Kato-Mori Y, et al: Thr(207) of claudin-5 is involved in size-selective loosening of the endothelial barrier by cyclic AMP. Exp Cell Res 300: 202-212, 2004.
57. Yuan L, Le Bras A, Sacharidou A, et al: ETS-related gene (ERG) controls endothelial cell permeability via transcriptional regulation of the claudin 5 (CLDN5) gene. J Biol Chem 287: 6582-6591, 2012.
58. Shen W, Li S, Chung SH, et al: Tyrosine phosphorylation of VE-cadherin and claudin-5 is associated with TGF-β1-induced permeability of centrally derived vascular endothelium. Eur J Cell Biol 90: 323-332, 2011.
59. Shimizu F, Sano Y, Saito K, et al: Pericyte-derived glial cell line-derived neurotrophic factor increase the expression of claudin-5 in the blood-brain barrier and the blood-nerve barrier. Neurochem Res 37: 401-409, 2012.
60. András IE and Toborek M: HIV-1-induced alterations of claudin-5 expression at the blood-brain barrier level. Methods Mol Biol 762: 355-370, 2011.
61. András IE, Pu H, Tian J, et al: Signaling mechanisms of HIV-1 Tat-induced alterations of claudin-5 expression in brain endothelial cells. J Cereb Blood Flow Metab 25: 1159-1170, 2005.
62. Liu LB, Xue YX, Liu YH and Wang YB: Bradykinin increases blood-tumor barrier permeability by down-regulating the expression levels of ZO-1, occludin, and claudin-5 and rearranging actin cytoskeleton. J Neurosci Res 86: 1153-1168, 2008.
63. Osada T, Gu YH, Kanazawa M, et al: Interendothelial claudin-5 expression depends on cerebral endothelial cell-matrix adhesion by β(1)-integrins. J Cereb Blood Flow Metab 31: 1972-1985, 2011.
64. Del Vecchio G, Tscheik C, Tenz K, et al: Sodium caprate transiently opens claudin-5-containing barriers at tight junctions of epithelial and endothelial cells. Mol Pharm 9: 2523-2533, 2012.
65. Liebner S, Fischmann A, Rascher G, et al: Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol 100: 323-331, 2000.
66. Chiba T, Kawachi H, Kawano T, et al: Independent histological risk factors for lymph node metastasis of superficial esophageal squamous cell carcinoma; implication of claudin-5 immunohistochemistry for expanding the indications of endoscopic resection. Dis Esophagus 23: 398-407, 2010.
67. Miyamori H, Takino T, Kobayashi Y, et al: Claudin promotes activation of pro-matrix metalloproteinase-2 mediated by membrane-type matrix metalloproteinases. J Biol Chem 276: 28204-28211, 2001.
68. Stamatovic SM, Keep RF, Wang MM, Jankovic I and Andjelkovic AV: Caveolae-mediated internalization of occludin and claudin-5 during CCL2-induced tight junction remodeling in brain endothelial cells. J Biol Chem 284: 19053-19066, 2009.
69. Stamatovic SM, Keep RF and Andjelkovic AV: Tracing the endocytosis of claudin-5 in brain endothelial cells. Methods Mol Biol 762: 303-320, 2011.
70. Escudero-Esparza A, Jiang WG and Martin TA: Claudin-5 is involved in breast cancer cell motility through the N-WASP and ROCK signalling pathways. J Exp Clin Cancer Res 31: 43, 2012.
71. Yamamoto M, Ramirez SH, Sato S, et al: Phosphorylation of claudin-5 and occludin by rho kinase in brain endothelial cells. Am J Pathol 172: 521-533, 2008.
72. Persidsky Y, Heilman D, Haorah J, et al: Rho-mediated regulation of tight junctions during monocyte migration across the blood-brain barrier in HIV-1 encephalitis (HIVE). Blood 107: 4770-4780, 2006.